Ohl D A, Naz R K
Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109, USA.
Urology. 1995 Oct;46(4):591-602. doi: 10.1016/S0090-4295(99)80282-9.
Immunoinfertility is an important problem, involving a significant number of infertile couples. Although the presence of antibodies on sperm has better prognostic value than those in serum or seminal plasma, it may not be the sole authentic evidence of immunoinfertility. Infertility from antisperm antibodies is likely only when they bind to a relevant sperm antigen involved in a specific fertility function. The variance in functional deficits seen in immunologic infertility is most likely related to antibodies directed at different sperm antigens or different class, subclass, or isotypes. Antibodies to FA-1 seem to be of significant importance in human immunoinfertility. In approaching couples with infertility, a high index of suspicion for antibodies is necessary to avoid misdiagnosis. In the optimal situation, all semen analyses should be screened for sperm-bound antibodies, but if this is impractical, testing should be performed on high-risk individuals (Table I). In couples in which the man has sperm-bound antibodies, and in whom there is no identifiable female factor, treatment should be instituted. Most treatments for immunoinfertility have been disappointing because of poor results, adverse effects, or high cost. Corticosteroid therapy has shown some promise in published reports (mostly poorly designed studies), but increase in pregnancy rate is modest and adverse effects may be significant. In our opinion, informed consent should be documented prior to institution of corticosteroid therapy, and subjects should be closely monitored. Advanced reproductive technologies offer a higher safety profile, and, with increasing technology, higher pregnancy rates. We recommend progressing from "low-tech" procedures, such as IUI and reserving the higher level procedures, such as IVF and ICSI, for those couples in whom pregnancy does not occur. The highest level reproductive technologies give the best current prospects for pregnancy in patients with this difficult problem but also are invasive and costly. It is hoped that further work in the laboratory will give rise to newer, safer, and less expensive effective treatments in the very near future.
免疫性不孕是一个重要问题,涉及大量不孕夫妇。尽管精子上抗体的存在比血清或精浆中的抗体具有更好的预后价值,但它可能不是免疫性不孕的唯一确凿证据。只有当抗精子抗体与参与特定生育功能的相关精子抗原结合时,才可能导致因抗精子抗体引起的不孕。免疫性不孕中所见功能缺陷的差异很可能与针对不同精子抗原或不同类别、亚类或同种型的抗体有关。针对FA-1的抗体似乎在人类免疫性不孕中具有重要意义。在处理不孕夫妇时,必须高度怀疑抗体的存在以避免误诊。在理想情况下,所有精液分析都应筛查精子结合抗体,但如果不实际可行,则应对高危个体进行检测(表I)。对于男性有精子结合抗体且无明确女性因素的夫妇,应开始治疗。大多数免疫性不孕的治疗效果都不尽人意,原因包括效果不佳、副作用或成本高昂。皮质类固醇疗法在已发表的报告中显示出一些希望(大多是设计不佳的研究),但妊娠率的提高幅度不大,且副作用可能很显著。我们认为,在开始皮质类固醇疗法之前应记录知情同意书,并且应对受试者进行密切监测。先进的生殖技术具有更高的安全性,并且随着技术的进步,妊娠率也更高。我们建议从“低技术”程序(如宫腔内人工授精)开始,对于未怀孕的夫妇保留更高水平的程序(如体外受精和卵胞浆内单精子注射)。最高水平的生殖技术为患有这一难题的患者提供了目前最佳的妊娠前景,但也是侵入性的且成本高昂。希望实验室的进一步工作能在不久的将来带来更新、更安全且成本更低的有效治疗方法。